Be part of the knowledge.
Register

We’re glad to see you’re enjoying ReachMD…
but how about a more personalized experience?

Register for free
  1. Home
  2. Programs
  3. CME/CE

Unlocking the Potential of HER2-Targeted Therapy: Breakthroughs in NSCLC Therapeutic Approaches

0.25 credits
15 minutes
ReachMD Healthcare Image
Restart
Resume
Choose a format
Take Post-Test Skip straight to the post-test if you have already participated in this activity.
Media formats available:
0.25 credits
Completing the pre-test is required to access this content.
Completing the pre-survey is required to view this content.

Ready to Claim Your Credits?

You have attempts to pass this post-test. Take your time and review carefully before submitting.

Good luck!

Details
Presenters
Related
Comments
  • Overview

    Dr. Helena Yu of Memorial Sloan Kettering Cancer Center presents an insightful overview of HER2 targeted therapy in non-small cell lung cancer (NSCLC), emphasizing the critical role of broad molecular profiling in ensuring effective treatment, particularly for the 2-4% of NSCLC patients with HER2 mutations. Dr. Yu highlights the effectiveness of newer antibody–drug conjugates (ADCs) such as trastuzumab deruxtecan (T-DXd) for NSCLC with HER2 mutations, while also detailing identification and management of potential side effects. Through a patient engagement vignette, she underscores the importance of aligning treatment choices with patient and clinician goals, highlighting shared decision-making in managing HER2-mutant NSCLC.

  • Disclosure of Relevant Financial Relationships

    In accordance with the ACCME Standards for Integrity and Independence, Global Learning Collaborative (GLC) requires that individuals in a position to control the content of an educational activity disclose all relevant financial relationships with any ineligible company. GLC mitigates all conflicts of interest to ensure independence, objectivity, balance, and scientific rigor in all its educational programs.

    Faculty:
    Helena Yu, MD
    Associate Attending
    Memorial Sloan Kettering Cancer Center
    New York, NY

    Dr. Yu has reported the following relevant financial relationships or relationships with ineligible companies of any amount during the past 24 months:
    Consulting Fees: Abbvie, AstraZeneca, Black Diamond, Blueprint, C4 Therapeutics, Cullinan, Daiichi Sankyo, Janssen, Ipsen, Takeda
    Research: AstraZeneca, Black Diamond, Blueprint, Cullinan, Daiichi Sankyo, ERASCA, Janssen, Novartis, Pfizer

    Reviewers/Content Planners/Authors:

    • Jorge Bacigalupo has nothing to disclose.
    • Cindy Davidson has nothing to disclose.
    • Ann Early has nothing to disclose.
    • Brian P. McDonough, MD, FAAFP, has nothing to disclose.
    • William Mencia, MD has nothing to disclose.
    • Tim Person has nothing to disclose.
    • Rosanne Strauss, PharmD, MBA has nothing to disclose.
    • Katie Sheridan has nothing to disclose.
    • Mara Siegel has nothing to disclose.
  • Learning Objectives

    After participating in this educational activity, participants should be better able to:

    • Distinguish the clinical significance of HER2-related genomic alterations when selecting the optimal testing methodology for broad application in patients with mNSCLC
    • Integrate comprehensive and longitudinal treatment strategies that optimize dosing, pulmonary/cardiac safety, and treatment of distant metastases for patients receiving HER2-directed therapies in NSCLC
  • Target Audience

    This activity is designed to meet the educational needs of medical oncologists, pathologists, oncology nurses, and oncology pharmacists.

  • Accreditation and Credit Designation Statements

    In support of improving patient care, Global Learning Collaborative (GLC) is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC) to provide continuing education for the healthcare team.

    Global Learning Collaborative (GLC) designates this enduring activity for a maximum of .25 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

    Global Learning Collaborative (GLC) designates this activity for .25 nursing contact hours. Nurses should claim only the credit commensurate with the extent of their participation in the activity.

    Global Learning Collaborative (GLC) has been authorized by the American Academy of PAs (AAPA) to award AAPA Category 1 CME credit for activities planned in accordance with AAPA CME Criteria. This activity is designated for .25 AAPA Category 1 CME credits. Approval is valid until February 28, 2025. PAs should claim only the credit commensurate with the extent of their participation in the activity.

    Global Learning Collaborative (GLC) designates this activity for .25 contact hours/.025 CEUs of pharmacy contact hours.1 

    The Universal Activity Number for this program is JA0006235-0000-24-002-H01-P. This learning activity is knowledge-based. Your CE credits will be electronically submitted to the NABP upon successful completion of the activity. Pharmacists with questions can contact NABP customer service (custserv@nabp.net). 

  • Provider(s)/Educational Partner(s)

    Prova Education designs and executes continuing education founded on evidence-based medicine, clinical need, gap analysis, learner feedback, and more. Our mission is to serve as an inventive and relevant resource for clinical content and educational interventions across a broad spectrum of specialties.

    Prova Education's methodology demonstrates a commitment to continuing medical education and the innovative assessment of its effects. Our goal is clear—to develop and deliver the very best education in the most impactful manner and to verify its results with progressive outcomes research.

  • Commercial Support

    This activity is supported by independent educational grants from AstraZeneca and Daiichi Sankyo, Inc.

  • Disclaimer

    The views and opinions expressed in this educational activity are those of the faculty and do not necessarily represent the views of GLC and Prova Education. This presentation is not intended to define an exclusive course of patient management; the participant should use his/her clinical judgment, knowledge, experience, and diagnostic skills in applying or adopting for professional use any of the information provided herein. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patients’ conditions and contraindications or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities. Links to other sites may be provided as additional sources of information. Once you elect to access a site outside of Prova Education you are subject to the terms and conditions of use, including copyright and licensing restriction, of that site.

    Reproduction Prohibited
    Reproduction of this material is not permitted without written permission from the copyright owner.

  • System Requirements

    • Supported Browsers (2 most recent versions):
      • Google Chrome for Windows, Mac OS, iOS, and Android
      • Apple Safari for Mac OS and iOS
      • Mozilla Firefox for Windows, Mac OS, iOS, and Android
      • Microsoft Edge for Windows
    • Recommended Internet Speed: 5Mbps+

  • Publication Dates

    Release Date:

    Expiration Date:

Recommended
Details
Presenters
Related
Comments
  • Overview

    Dr. Helena Yu of Memorial Sloan Kettering Cancer Center presents an insightful overview of HER2 targeted therapy in non-small cell lung cancer (NSCLC), emphasizing the critical role of broad molecular profiling in ensuring effective treatment, particularly for the 2-4% of NSCLC patients with HER2 mutations. Dr. Yu highlights the effectiveness of newer antibody–drug conjugates (ADCs) such as trastuzumab deruxtecan (T-DXd) for NSCLC with HER2 mutations, while also detailing identification and management of potential side effects. Through a patient engagement vignette, she underscores the importance of aligning treatment choices with patient and clinician goals, highlighting shared decision-making in managing HER2-mutant NSCLC.

  • Disclosure of Relevant Financial Relationships

    In accordance with the ACCME Standards for Integrity and Independence, Global Learning Collaborative (GLC) requires that individuals in a position to control the content of an educational activity disclose all relevant financial relationships with any ineligible company. GLC mitigates all conflicts of interest to ensure independence, objectivity, balance, and scientific rigor in all its educational programs.

    Faculty:
    Helena Yu, MD
    Associate Attending
    Memorial Sloan Kettering Cancer Center
    New York, NY

    Dr. Yu has reported the following relevant financial relationships or relationships with ineligible companies of any amount during the past 24 months:
    Consulting Fees: Abbvie, AstraZeneca, Black Diamond, Blueprint, C4 Therapeutics, Cullinan, Daiichi Sankyo, Janssen, Ipsen, Takeda
    Research: AstraZeneca, Black Diamond, Blueprint, Cullinan, Daiichi Sankyo, ERASCA, Janssen, Novartis, Pfizer

    Reviewers/Content Planners/Authors:

    • Jorge Bacigalupo has nothing to disclose.
    • Cindy Davidson has nothing to disclose.
    • Ann Early has nothing to disclose.
    • Brian P. McDonough, MD, FAAFP, has nothing to disclose.
    • William Mencia, MD has nothing to disclose.
    • Tim Person has nothing to disclose.
    • Rosanne Strauss, PharmD, MBA has nothing to disclose.
    • Katie Sheridan has nothing to disclose.
    • Mara Siegel has nothing to disclose.
  • Learning Objectives

    After participating in this educational activity, participants should be better able to:

    • Distinguish the clinical significance of HER2-related genomic alterations when selecting the optimal testing methodology for broad application in patients with mNSCLC
    • Integrate comprehensive and longitudinal treatment strategies that optimize dosing, pulmonary/cardiac safety, and treatment of distant metastases for patients receiving HER2-directed therapies in NSCLC
  • Target Audience

    This activity is designed to meet the educational needs of medical oncologists, pathologists, oncology nurses, and oncology pharmacists.

  • Accreditation and Credit Designation Statements

    In support of improving patient care, Global Learning Collaborative (GLC) is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC) to provide continuing education for the healthcare team.

    Global Learning Collaborative (GLC) designates this enduring activity for a maximum of .25 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

    Global Learning Collaborative (GLC) designates this activity for .25 nursing contact hours. Nurses should claim only the credit commensurate with the extent of their participation in the activity.

    Global Learning Collaborative (GLC) has been authorized by the American Academy of PAs (AAPA) to award AAPA Category 1 CME credit for activities planned in accordance with AAPA CME Criteria. This activity is designated for .25 AAPA Category 1 CME credits. Approval is valid until February 28, 2025. PAs should claim only the credit commensurate with the extent of their participation in the activity.

    Global Learning Collaborative (GLC) designates this activity for .25 contact hours/.025 CEUs of pharmacy contact hours.1 

    The Universal Activity Number for this program is JA0006235-0000-24-002-H01-P. This learning activity is knowledge-based. Your CE credits will be electronically submitted to the NABP upon successful completion of the activity. Pharmacists with questions can contact NABP customer service (custserv@nabp.net). 

  • Provider(s)/Educational Partner(s)

    Prova Education designs and executes continuing education founded on evidence-based medicine, clinical need, gap analysis, learner feedback, and more. Our mission is to serve as an inventive and relevant resource for clinical content and educational interventions across a broad spectrum of specialties.

    Prova Education's methodology demonstrates a commitment to continuing medical education and the innovative assessment of its effects. Our goal is clear—to develop and deliver the very best education in the most impactful manner and to verify its results with progressive outcomes research.

  • Commercial Support

    This activity is supported by independent educational grants from AstraZeneca and Daiichi Sankyo, Inc.

  • Disclaimer

    The views and opinions expressed in this educational activity are those of the faculty and do not necessarily represent the views of GLC and Prova Education. This presentation is not intended to define an exclusive course of patient management; the participant should use his/her clinical judgment, knowledge, experience, and diagnostic skills in applying or adopting for professional use any of the information provided herein. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patients’ conditions and contraindications or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities. Links to other sites may be provided as additional sources of information. Once you elect to access a site outside of Prova Education you are subject to the terms and conditions of use, including copyright and licensing restriction, of that site.

    Reproduction Prohibited
    Reproduction of this material is not permitted without written permission from the copyright owner.

  • System Requirements

    • Supported Browsers (2 most recent versions):
      • Google Chrome for Windows, Mac OS, iOS, and Android
      • Apple Safari for Mac OS and iOS
      • Mozilla Firefox for Windows, Mac OS, iOS, and Android
      • Microsoft Edge for Windows
    • Recommended Internet Speed: 5Mbps+

  • Publication Dates

    Release Date:

    Expiration Date:

Schedule12 Nov 2024